Zachary Bessette

Zachary Bessette

Articles by Zachary Bessette

Zachary BessettemCSPC | April 27, 2025
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Read More
Zachary BessettenccRCC | April 27, 2025
CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.
Zachary BessetteLocalized Renal Cell Carcinoma | April 27, 2025
A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.
Zachary BessetteLocalized | April 26, 2025
Research sheds light on the patient-reported outcomes from a 3-year focal therapy program for localized PCa using HIFU.
Zachary BessetteUrothelial Carcinoma | April 27, 2025
Interim data may support the use of light-activated TLD-1433 photodynamic therapy for patients with BCG–unresponsive NMIBC.
Zachary BessetteUrothelial Carcinoma | April 27, 2025
Dr. Roberto Contieri presented on the safety, tolerability, and efficacy of neoadjuvant mitomycin C in patients with NMIBC.
Zachary BessetteCRPC | February 13, 2025
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
Zachary BessetteRenal Cell Carcinoma | February 18, 2025
Increased levels of circulating KIM-1 are associated with worse outcomes for patients receiving nivo/ipi or sunitinib alone.
Zachary BessetteRenal Cell Carcinoma | January 2, 2025
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Zachary BessetteCRPC | October 1, 2024
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | September 17, 2024
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | September 17, 2024
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Zachary BessetteAdvanced Urothelial Carcinoma | September 13, 2024
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Zachary BessetteAdvanced Urothelial Carcinoma | September 12, 2024
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Zachary BessetteMuscle Invasive Urothelial Carcinoma | September 11, 2024
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
Zachary BessetteProstate Cancer Diagnostics | July 24, 2024
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Zachary BessetteRLT | June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Zachary BessetteProstate Cancer Diagnostics | June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Zachary BessetteCRPC | June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Zachary BessetteCRPC | June 3, 2024
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.